NPM1 is an inclusion criterion in 125 clinical trials for acute myeloid leukemia, of which 92 are open and 33 are closed. Of the trials that contain NPM1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 45 are phase 1 (32 open), 23 are phase 1/phase 2 (18 open), 43 are phase 2 (31 open), 4 are phase 2/phase 3 (3 open), 8 are phase 3 (7 open), and 1 is no phase specified (1 open) [4].

NPM1 is an inclusion criterion in 122 clinical trials for myelodysplastic syndromes, of which 90 are open and 32 are closed. Of the trials that contain NPM1 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (0 open), 50 are phase 1 (35 open), 23 are phase 1/phase 2 (18 open), 33 are phase 2 (25 open), 2 are phase 2/phase 3 (1 open), 11 are phase 3 (9 open), and 2 are no phase specified (2 open) [4].

NPM1 is an inclusion criterion in 31 clinical trials for acute lymphoblastic leukemia, of which 23 are open and 8 are closed. Of the trials that contain NPM1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 8 are phase 1 (5 open), 7 are phase 1/phase 2 (7 open), 13 are phase 2 (9 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [4].

NPM1 is an inclusion criterion in 29 clinical trials for chronic myelomonocytic leukemia, of which 23 are open and 6 are closed. Of the trials that contain NPM1 status and chronic myelomonocytic leukemia as inclusion criteria, 10 are phase 1 (7 open), 8 are phase 1/phase 2 (8 open), 9 are phase 2 (7 open), and 2 are phase 3 (1 open) [4].

NPM1 is an inclusion criterion in 13 clinical trials for malignant solid tumor, of which 10 are open and 3 are closed. Of the trials that contain NPM1 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [4].

NPM1 is an inclusion criterion in 11 clinical trials for chronic myeloid leukemia, of which 8 are open and 3 are closed. Of the trials that contain NPM1 status and chronic myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 4 are phase 2 (3 open) [4].

NPM1 is an inclusion criterion in 9 clinical trials for hodgkin lymphoma, of which 6 are open and 3 are closed. Of the trials that contain NPM1 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (5 open) [4].

NPM1 is an inclusion criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain NPM1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [4].

NPM1 is an inclusion criterion in 8 clinical trials for mantle cell lymphoma, of which 4 are open and 4 are closed. Of the trials that contain NPM1 status and mantle cell lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 5 are phase 2 (3 open) [4].

NPM1 is an inclusion criterion in 8 clinical trials for multiple myeloma, of which 6 are open and 2 are closed. Of the trials that contain NPM1 status and multiple myeloma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [4].

NPM1 is an inclusion criterion in 8 clinical trials for non-hodgkin lymphoma, of which 6 are open and 2 are closed. Of the trials that contain NPM1 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 4 are phase 2 (4 open) [4].

NPM1 is an inclusion criterion in 7 clinical trials for acute leukemia, of which 5 are open and 2 are closed. Of the trials that contain NPM1 status and acute leukemia as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [4].

NPM1 is an inclusion criterion in 7 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 7 are open and 0 are closed. Of the trials that contain NPM1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 7 are phase 2 (7 open) [4].

NPM1 is an inclusion criterion in 6 clinical trials for anaplastic large cell lymphoma, of which 3 are open and 3 are closed. Of the trials that contain NPM1 status and anaplastic large cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 5 are phase 2 (3 open) [4].

NPM1 is an inclusion criterion in 6 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 5 are open and 1 is closed. Of the trials that contain NPM1 status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain NPM1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].

NPM1 is an inclusion criterion in 6 clinical trials for refractory anemia with excess blasts, of which 5 are open and 1 is closed. Of the trials that contain NPM1 status and refractory anemia with excess blasts as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 5 clinical trials for Burkitt lymphoma, of which 3 are open and 2 are closed. Of the trials that contain NPM1 status and Burkitt lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (3 open) [4].

NPM1 is an inclusion criterion in 5 clinical trials for follicular lymphoma, of which 3 are open and 2 are closed. Of the trials that contain NPM1 status and follicular lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (3 open) [4].

NPM1 is an inclusion criterion in 5 clinical trials for marginal zone lymphoma, of which 3 are open and 2 are closed. Of the trials that contain NPM1 status and marginal zone lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (3 open) [4].

NPM1 is an inclusion criterion in 5 clinical trials for mixed phenotype acute leukemia, of which 5 are open and 0 are closed. Of the trials that contain NPM1 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [4].

NPM1 is an inclusion criterion in 5 clinical trials for myelofibrosis, of which 3 are open and 2 are closed. Of the trials that contain NPM1 status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (1 open), and 2 are phase 2 (2 open) [4].

NPM1 is an inclusion criterion in 4 clinical trials for acute biphenotypic leukemia, of which 4 are open and 0 are closed. Of the trials that contain NPM1 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [4].

NPM1 is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain NPM1 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [4].

NPM1 is an inclusion criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 1 is closed. Of the trials that contain NPM1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 4 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 2 are open and 2 are closed. Of the trials that contain NPM1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 4 are phase 2 (2 open) [4].

NPM1 is an inclusion criterion in 4 clinical trials for myeloproliferative neoplasm, of which 3 are open and 1 is closed. Of the trials that contain NPM1 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (2 open) [4].

NPM1 is an inclusion criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain NPM1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [4].

NPM1 is an inclusion criterion in 4 clinical trials for secondary acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain NPM1 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

NPM1 is an inclusion criterion in 4 clinical trials for therapy-related acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain NPM1 status and therapy-related acute myeloid leukemia as inclusion criteria, 4 are phase 2 (4 open) [4].

NPM1 is an inclusion criterion in 3 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain NPM1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NPM1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 3 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain NPM1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 3 are phase 2 (2 open) [4].

NPM1 is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NPM1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [4].

NPM1 is an inclusion criterion in 3 clinical trials for diffuse large B-cell lymphoma, of which 1 is open and 2 are closed. Of the trials that contain NPM1 status and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (0 open) [4].

NPM1 is an inclusion criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain NPM1 status and lymphoplasmacytic lymphoma as inclusion criteria, 3 are phase 2 (2 open) [4].

NPM1 is an inclusion criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain NPM1 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 3 clinical trials for secondary myelodysplastic syndrome, of which 1 is open and 2 are closed. Of the trials that contain NPM1 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

NPM1 is an inclusion criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain NPM1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for acute promyelocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain NPM1 status and acute promyelocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for acute undifferentiated leukemia, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and acute undifferentiated leukemia as inclusion criteria, 2 are phase 2 (2 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 1 is open and 1 is closed. Of the trials that contain NPM1 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for blastic plasmacytoid dendritic cell neoplasm, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and blastic plasmacytoid dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for chronic myelomonocytic leukemia-1, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and chronic myelomonocytic leukemia-1 as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (1 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NPM1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for lymphoblastic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and lymphoblastic lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for lymphoma, of which 0 are open and 2 are closed. Of the trials that contain NPM1 status and lymphoma as inclusion criteria, 2 are phase 1 (0 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain NPM1 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NPM1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for plasma cell leukemia, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and plasma cell leukemia as inclusion criteria, 2 are phase 2 (2 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for prolymphocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and prolymphocytic leukemia as inclusion criteria, 2 are phase 2 (2 open) [4].

NPM1 is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for acute bilineal leukemia, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and acute bilineal leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for aggressive non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and aggressive non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for B-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-0, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and chronic myelomonocytic leukemia-0 as inclusion criteria, 1 is no phase specified (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 3 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and myeloid sarcoma as inclusion criteria, 1 is phase 3 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for NK-cell lymphoma, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and NK-cell lymphoma, unclassifiable as inclusion criteria, 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for refractory anemia, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and refractory anemia as inclusion criteria, 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for refractory anemia with ring sideroblasts, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and refractory anemia with ring sideroblasts as inclusion criteria, 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for Richter syndrome, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and Richter syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and systemic mastocytosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for T-cell lymphoblastic leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for therapy-related myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and therapy-related myeloid neoplasm as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

NPM1 is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].